Journal of gerontological nursing · 2026
Understanding and Managing Immunoglobulin A Nephropathy.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Romano Kate K, Brodeur Michael R, Grabe Darren W
Аннотация
PURPOSE: Immunoglobulin A nephropathy (IgAN) is the most common pattern of primary glomerular disease worldwide and remains a leading cause of chronic kidney disease and kidney failure. The intent of the current article is to review the 2025 Clinical Practice Guideline from Kidney Disease: Improving Global Outcomes (KDIGO) for the management of IgAN and summarize updated evidence-based diagnostic and therapeutic strategies.
METHOD: Current literature, clinical evidence, and guideline recommendations on the management of IgAN are reviewed.
RESULTS: The updated guideline emphasizes early biopsy-confirmed diagnosis, proteinuria-guided risk assessment, and optimized supportive care, including strict blood pressure control and kidney protective therapies. In addition, newer disease-specific treatments that target pathogenic forms of IgA and IgA-immune complexes should be used simultaneously.
CONCLUSION: The 2025 KDIGO guideline advances IgAN management through an interdisciplinary, multi-targeted, evidence-based approach aimed at reducing proteinuria, preserving kidney function, and improving long-term renal outcomes.
METHOD: Current literature, clinical evidence, and guideline recommendations on the management of IgAN are reviewed.
RESULTS: The updated guideline emphasizes early biopsy-confirmed diagnosis, proteinuria-guided risk assessment, and optimized supportive care, including strict blood pressure control and kidney protective therapies. In addition, newer disease-specific treatments that target pathogenic forms of IgA and IgA-immune complexes should be used simultaneously.
CONCLUSION: The 2025 KDIGO guideline advances IgAN management through an interdisciplinary, multi-targeted, evidence-based approach aimed at reducing proteinuria, preserving kidney function, and improving long-term renal outcomes.